LaFleur & Godfrey LLC Sells 4,876 Shares of Zoetis Inc. $ZTS

LaFleur & Godfrey LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 24.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,674 shares of the company’s stock after selling 4,876 shares during the quarter. LaFleur & Godfrey LLC’s holdings in Zoetis were worth $1,846,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Summit Place Financial Advisors LLC boosted its stake in shares of Zoetis by 0.4% in the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after buying an additional 76 shares during the last quarter. CWA Asset Management Group LLC increased its position in shares of Zoetis by 1.1% during the third quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock valued at $1,059,000 after acquiring an additional 80 shares during the last quarter. RFG Advisory LLC lifted its holdings in Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after acquiring an additional 80 shares during the period. YANKCOM Partnership lifted its holdings in Zoetis by 3.5% during the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after acquiring an additional 81 shares during the period. Finally, Evergreen Capital Management LLC boosted its position in Zoetis by 3.3% in the third quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after purchasing an additional 85 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ZTS shares. Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Bank of America raised their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Citigroup initiated coverage on shares of Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Finally, UBS Group decreased their target price on Zoetis from $136.00 to $130.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $151.75.

Zoetis Stock Down 0.1%

Shares of NYSE ZTS opened at $112.60 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a market cap of $47.36 billion, a P/E ratio of 18.70, a P/E/G ratio of 1.73 and a beta of 0.87. Zoetis Inc. has a 52 week low of $111.27 and a 52 week high of $172.23. The business has a 50-day simple moving average of $119.61 and a two-hundred day simple moving average of $124.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the prior year, the business posted $1.40 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts anticipate that Zoetis Inc. will post 7.01 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.9%. Zoetis’s dividend payout ratio is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.